Psoriasis

UCB’s Cimzia (certolizumab pegol) was recommended for approval by the European Committee for Medicinal Products (CHMP) for the treatment of adult patients with moderate-to-severe plaque psoriasis.

Physicians may want to reconsider goals for the treatment of plaque psoriasis. In this study, physicians describe utilizing treat-to-target with a patient-centered approach to care for symptom relief.

As the list of treatments for plaque psoriasis grows, so does the list of adverse events associated with biologic treatment. In this article, we summarize adverse events associated with common treatments for plaque psoriasis.

Immune cell derivative itaconate may combat psoriasis and other autoimmune diseases, shows a study in Nature.

"Plaque psoriasis is increasingly recognized as a multisystemic disease whose most common comorbidities include psoriatic arthritis, cardiovascular disease, metabolic syndrome, overweight/obesity, inflammatory bowel disease, and depression. The presence of such comorbidities affects the therapeutic choices for clinicians," researchers write in Seminars in Cutaneous Medicine and Surgery.

Dermatologists play a significant role in screening for psoriasis comorbidities and asking about shortness of breath as a routine part of medical history-taking, shows a study published in BMJ.